Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 18/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5014112 | 0.94 | P2RY12 (0.63) | P2RY12CYP3A4CYP2C9KDM4ECHRM2 | |
| SCHEMBL5592386 | 0.94 | P2RY12 (0.63) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL5014008 | 0.93 | P2RY12 (0.62) | P2RY12CYP3A4CYP2C9KDM4ECHRM2 | |
| SCHEMBL29258844 | 0.92 | P2RY12 (0.65) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL30999839 | 0.92 | P2RY12 (0.65) | P2RY12CYP3A4CYP2C9CHRM2DRD3 | |
| SCHEMBL4877269 | 0.89 | P2RY12 (0.57) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL4740960 | 0.89 | P2RY12 (0.57) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL4115190 | 0.89 | P2RY12 (0.70) | P2RY12CYP3A4CYP2C9KDM4ECHRM2 | |
| SCHEMBL4875331 | 0.89 | P2RY12 (0.56) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL3327054 | 0.88 | P2RY12 (0.56) | P2RY12CYP3A4CYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344351-A | Preparation method and application of PET imaging agent targeting neuroinflammatory purinergic P2Y12 receptor | 复旦大学 | 2024-07-16 | — | — | CN | disclosed |
| WO-2010005385-A1 | 2-AMINO-6-ALKYL SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS P2Y12 INHIBITORS 308 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | WO | disclosed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090186876-A1 | Pyridine Analogues II | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| EP-2041111-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080176827-A1 | New Pyridine Analogues VII 543 | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008085118-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008002247-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20070244088-A1 | New Pyridine Analogues II | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176827-A1 | New Pyridine Analogues VII 543 | P2RY12, P2RY11, P2RY4 | P2RY12 1/4885CYP3A4 254/4885CYP2C9 387/4885 |
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP3A4 801/4885CYP2C9 853/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885CYP3A4 324/4885CYP2C9 453/4885 |
| US-20070244088-A1 | New Pyridine Analogues II | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885CYP3A4 235/4885CYP2C9 416/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP3A4 140/4885CYP2C9 96/4885 |
| US-20090186876-A1 | Pyridine Analogues II | P2RY12, P2RY11, P2RY6 | P2RY12 1/4885CYP3A4 375/4885CYP2C9 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.